Evidence map›Paper›PMID 29416666›Full record

ArticleOncotarget2018

Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.

Kei Kawaguchi, Kentaro Igarashi, Shukuan Li, Qinghong Han, Yuying Tan, Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Takashi Murakami, Bartosz Chmielowski and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Characterization of methionine dependence in melanoma cells.bioRxiv : the preprint server for biology · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Kei KawaguchiAntiCancer, Inc., San Diego, CA, USA.
Kentaro IgarashiAntiCancer, Inc., San Diego, CA, USA.
Shukuan LiAntiCancer, Inc., San Diego, CA, USA.
Qinghong HanAntiCancer, Inc., San Diego, CA, USA.
Yuying TanAntiCancer, Inc., San Diego, CA, USA.
Kentaro MiyakeAntiCancer, Inc., San Diego, CA, USA.
Tasuku KiyunaAntiCancer, Inc., San Diego, CA, USA.
Masuyo MiyakeAntiCancer, Inc., San Diego, CA, USA.
Takashi MurakamiAntiCancer, Inc., San Diego, CA, USA.
Bartosz ChmielowskiDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Scott D NelsonDepartment of Pathology, University of California, Los Angeles, CA, USA.
Tara A RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Sarah M DryDepartment of Pathology, University of California, Los Angeles, CA, USA.
Yunfeng LiDepartment of Pathology, University of California, Los Angeles, CA, USA.
Michiaki UnnoDepartment of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Robert M HoffmanAntiCancer, Inc., San Diego, CA, USA.
AntiCancer (United States) · USUniversity of California, Los Angeles · USTohoku University · JPUniversity of California, San Diego · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042
6 · The paper itself

Abstract

Melanoma is a recalcitrant disease. Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation. However, we previously showed that VEM is not very effective against a BRAF-V600E melanoma mutant in a patient-derived orthotopic xenograft (PDOX) model. In contrast, we demonstrated that recombinant methioninase (rMETase) which targets the general metabolic defect in cancer of methionine dependence, was effective against the BRAF-V600E mutant melanoma PDOX model. In the present study, we demonstrate that rMETase is effective against a BRAF-V600E-negative melanoma PDOX which we established. Forty BRAF-V600E-negative melanoma PDOX mouse models were randomized into four groups of 10 mice each: untreated control (

Indexed as

BRAF-V600E mutationmelanomamethionine dependencePDOXrecombinant methioninase

Identifiers

PMID29416666
PMCPMC5787523
OpenAlexW2771508138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.